Read + Share
Amedeo Smart
Independent Medical Education
Carbone S, DaSilva-deAbreu A, Lavie CJ. The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox. Eur J Heart Fail 2021 Aug 23. doi: 10.1002/ejhf.2336.PMID: 34427026
Email
LinkedIn
Facebook
Twitter
Privacy Policy